AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30059487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for survival prediction
Number of subjects: 376
Study 26684437 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 64
Study 26684437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 25554212 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus 3.11 apheresis separator
Number of subjects: 98
Study 25554212 — intervention group
Group type: COMPARATOR
Intervention: Trima 5.22 apheresis separator
Number of subjects: 98
Study 23948830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise
Number of subjects: 42
Study 23948830 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Number of subjects: 42
Study 23948830 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 42
Study 20306017 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training group including vibration (TGV)
Number of subjects: 151
Study 20306017 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training group (TG)
Number of subjects: 151
Study 20306017 — intervention group
Group type: COMPARATOR
Intervention: Wellness control group (CG)
Number of subjects: 151
Study 19399934 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib infusion 30 min before induction of anesthesia and at 12 h after the first dose
Number of subjects: 70
Study 19399934 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion as placebo
Number of subjects: 70
Study 17645463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week furazolidone-based quadruple therapy (FABO1)
Number of subjects: 156
Study 17645463 — intervention group
Group type: COMPARATOR
Intervention: 2-week furazolidone-based quadruple therapy (FABO2)
Number of subjects: 156
Study 14679124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day) concomitantly with EC chemotherapy (epirubicin 75 mg/m² + cyclophosphamide 600 mg/m² on day 1, every 21 days for four cycles)
Number of subjects: 485
Study 14679124 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen administered sequentially with EC chemotherapy
Number of subjects: 485
Study 14679124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (CON and SEQ)
Number of subjects: 485
Study 11294406 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour laparoscopic dissection in a fresh cadaver
Number of subjects: 28
Study 11294406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laparoscopic dissection)
Number of subjects: 28
Study 9633980 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 102
Study 9633980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX)
Number of subjects: 102
Study 9633980 — intervention group
Group type: COMPARATOR
Intervention: Parental report
Number of subjects: 102
Study 9633980 — intervention group
Group type: COMPARATOR
Intervention: Side-effects
Number of subjects: 102
Study 7889884 — intervention group
Group type: EXPERIMENTAL
Intervention: High boron intake (approximately 3.25 mg boron/2000 kcal/day)
Number of subjects: 3
Study 7889884 — intervention group
Group type: COMPARATOR
Intervention: Low boron intake (approximately 0.25 mg boron/2000 kcal/day)
Number of subjects: 3
Study 3144581 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 3144581 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 3144581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0
Study 3144581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29847413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐PTM (telephone-based Progressive Tinnitus Management)
Number of subjects: 205
Study 29847413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐PTM
Number of subjects: 205
Study 29847413 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 205
Study 28142391 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor
Number of subjects: 195
Study 28142391 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 195
Study 26297786 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Pulmonary vein isolation (PVI) with adenosine challenge
Number of subjects: 152
Study 26297786 — intervention group
Group type: COMPARATOR
Intervention: Group B: PVI with AF source ablation if AF did not terminate
Number of subjects: 152
Study 26297786 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: PVI
Number of subjects: 152
Study 26297786 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: AF source ablation
Number of subjects: 152
Study 26297786 — intervention group
Group type: COMPARATOR
Intervention: Group B: PVI
Number of subjects: 152
Study 23328566 — intervention group
Group type: EXPERIMENTAL
Intervention: TCFA at baseline
Number of subjects: 63
Study 23328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly classified TCFA lesions at follow-up
Number of subjects: 63
Study 23328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum lumen area (MLA)
Number of subjects: 63
Study 23328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent necrotic core at MLA site
Number of subjects: 63
Study 23328566 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent necrotic core over entire length of lesion
Number of subjects: 63
Study 21791093 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (or hydromorphone)
Number of subjects: 232
Study 21791093 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 232
Study 18720053 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste
Number of subjects: 17
Study 18720053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Number of subjects: 17
Study 18720053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low air content slurry (LA)
Number of subjects: 17
Study 18720053 — intervention group
Group type: EXPERIMENTAL
Intervention: High air content slurry (HA)
Number of subjects: 17
Study 18720053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16957408 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 53
Study 15087410 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 10611201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20
Study 10611201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9106017 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin at 10 mg/kg once daily for 3 days
Number of subjects: 100
Study 9106017 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin at 15 mg/kg per day divided into two equal doses for 10 days
Number of subjects: 100
Study 9106017 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 100
Study 9106017 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 100
Study 9106017 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and Clarithromycin
Number of subjects: 100
Study 1539850 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (approximately 0.6%)
Number of subjects: 23
Study 1539850 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.9%) with caudal analgesia
Number of subjects: 23
Study 1539850 — intervention group
Group type: COMPARATOR
Intervention: Halothane (0.9%) with penile nerve block
Number of subjects: 23
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: 50, 100, and 200 micrograms ovine Corticotropin releasing factor (oCRF)
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 and 100 micrograms human synthetic CRF
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms CRF dosage
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF test
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticoid therapy
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF administration
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRF administration
Number of subjects: 9
Study 2986422 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous CRF levels measured by oCRF radioimmunoassay
Number of subjects: 9
Study 30067553 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment negative affectivity (NA)
Number of subjects: 288
Study 30067553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment positive affectivity (PA)
Number of subjects: 288
Study 29248964 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC insertion strategy (CVCi)
Number of subjects: 25348
Study 29248964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene promotion strategy (HHi)
Number of subjects: 25348
Study 29248964 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined (COMBi)
Number of subjects: 25348
Study 29248964 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC insertion score
Number of subjects: 25348
Study 29248964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene compliance
Number of subjects: 25348
Study 26762123 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRETp) combined with treatment as usual (TAU)
Number of subjects: 0
Study 26762123 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition receiving treatment as usual (TAU) only
Number of subjects: 0
Study 24630505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lamivudine/adefovir dipivoxil (Lam/Adv)
Number of subjects: 38
Study 24630505 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 1mg
Number of subjects: 38
Study 24630505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 38
Study 22440335 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition simulating testing anxiety
Number of subjects: 58
Study 22440335 — intervention group
Group type: COMPARATOR
Intervention: Control (no stress induction)
Number of subjects: 58
Study 22440335 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of cortisol at session arrival
Number of subjects: 58
Study 22440335 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cortisol
Number of subjects: 58
Study 20185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 0
Study 20185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0
Study 20185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 0
Study 20185975 — intervention group
Group type: COMPARATOR
Intervention: Topical glucocorticoids (TGC)
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin/pregabalin
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin and noradrenaline-reuptake inhibitors
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patches
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine or oxcarbazepine
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 18685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 0
Study 15892796 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs for treating metastatic renal cancer
Number of subjects: 0
Study 12194632 — intervention group
Group type: EXPERIMENTAL
Intervention: Airmax salbutamol (100-400 micrograms)
Number of subjects: 61
Study 12194632 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Ventolin (100-400 micrograms)
Number of subjects: 61
Study 12194632 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskhaler (100-400 micrograms)
Number of subjects: 61
Study 12194632 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Accuhaler (100-400 micrograms)
Number of subjects: 61
Study 12194632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10703303 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one nurse/patient teaching
Number of subjects: 0
Study 10703303 — intervention group
Group type: COMPARATOR
Intervention: One-to-one nurse/patient teaching plus take-home instructional chemotherapy video
Number of subjects: 0
Study 8611831 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 47
Study 8611831 — intervention group
Group type: COMPARATOR
Intervention: Non-specific counselling (Control)
Number of subjects: 47
Study 2035504 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Insurance Plan of Greater New York trial (intervention group)
Number of subjects: 0
Study 7021262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 87
Study 7021262 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC‐30 (ASA 375 mg; codeine phosphate 30 mg; caffeine citrate 30 mg)
Number of subjects: 87
Study 7021262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 31769886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 361
Study 31769886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 361
Study 31769886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg/d
Number of subjects: 361
Study 31769886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (all doses)
Number of subjects: 361
Study 31769886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/d)
Number of subjects: 361
Study 29739848 — intervention group
Group type: EXPERIMENTAL
Intervention: Training needle device
Number of subjects: 23
Study 29739848 — intervention group
Group type: COMPARATOR
Intervention: Cotton tip applicator
Number of subjects: 23
Study 28272840 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed intervention addressing intimate partner violence and reproductive coercion
Number of subjects: 49
Study 26320293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (12.5 mg/day)
Number of subjects: 31
Study 26320293 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (13.3 mg/day) + Ezetimibe (10 mg)
Number of subjects: 31
Study 23420550 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills‐building intervention
Number of subjects: 422
Study 23420550 — intervention group
Group type: COMPARATOR
Intervention: Wellness control session
Number of subjects: 422
Study 21139020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at 25 Gy
Number of subjects: 720
Study 21139020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at 36 Gy
Number of subjects: 720
Study 18331927 — intervention group
Group type: EXPERIMENTAL
Intervention: Onplant (Nobel Biocare)
Number of subjects: 120
Study 18331927 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosystem implant (Institut Straumann AG)
Number of subjects: 120
Study 18331927 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 120
Study 18331927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpalatal bar
Number of subjects: 120
Study 16594932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid gel (LVG)
Number of subjects: 90
Study 16594932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus lactic acid gel
Number of subjects: 90
Study 16594932 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 90
Study 12477508 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (estradiol, 2 mg/d, and norethisterone acetate, 1 mg/d)
Number of subjects: 61
Study 12477508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9816618 — intervention group
Group type: EXPERIMENTAL
Intervention: SH U 508 A (Levovist)
Number of subjects: 588
Study 9816618 — intervention group
Group type: COMPARATOR
Intervention: Dynamic CT
Number of subjects: 588
Study 7654045 — intervention group
Group type: COMPARATOR
Intervention: 5 FU alone (A)
Number of subjects: 91
Study 7654045 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 FU with levamisole (II)
Number of subjects: 91
Study 7654045 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 FU with folinic acid (B)
Number of subjects: 91
Study 2709206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic therapy (Group I)
Number of subjects: 96
Study 2709206 — intervention group
Group type: COMPARATOR
Intervention: Nonantibiotic treatment (Group II)
Number of subjects: 96
Study 1101757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol alone
Number of subjects: 20
Study 1101757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propranolol and digoxin
Number of subjects: 20
Study 6103766 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic LHRH (HOE 471) administered intranasally for 4 weeks
Number of subjects: 19
Study 6103766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31091136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic Prognostic Index (PI) based on multivariable Cox model
Number of subjects: 1635
Study 31091136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic abnormalities t(4;14) or del(17p)
Number of subjects: 1635
Study 31091136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic PI
Number of subjects: 1635
Study 29423508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postnatal serum levels of arachidonic acid (AA) (20:4 ω‐6)
Number of subjects: 90
Study 29423508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postnatal serum levels of arachidonic acid (AA) (20:4 ω‐6) and gestational age at birth
Number of subjects: 90
Study 26529616 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol variability
Number of subjects: 52
Study 26529616 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of rejection in response to the laboratory stressor at month 8
Number of subjects: 52
Study 25089310 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer intervention (dietary and pharmacologic education, follow-up calls within 48 hours, and weekly calls for a month)
Number of subjects: 137
Study 25089310 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer intervention
Number of subjects: 137
Study 25089310 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 137
Study 22828032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feeding (Group A) administered in 10 minutes followed by continuous feeding for 3 hours.
Number of subjects: 20
Study 22828032 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding (Group B) administered over 3 hours followed by bolus feeding in 10 minutes.
Number of subjects: 20
Study 19348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 0
Study 19348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0
Study 19348539 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study 17164234 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed medications (average 3.7 prescribed medicines)
Number of subjects: 466
Study 17164234 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) drugs (average 1.4 OTC drugs)
Number of subjects: 466
Study 17164234 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants predicting polypharmacy: breathlessness, hypertension, dependency on instrumental activities of daily living, low subjective health, medication disagreement between doctors and patients
Number of subjects: 466
Study 15616613 — intervention group
Group type: COMPARATOR
Intervention: Inborn delivery
Number of subjects: 898
Study 15616613 — intervention group
Group type: EXPERIMENTAL
Intervention: Outborn delivery
Number of subjects: 898
Study 12167118 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 68
Study 12167118 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 68
Study 12167118 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 68
Study 12167118 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin + Omeprazole
Number of subjects: 68
Study 10208393 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage leukofiltered blood products (group B)
Number of subjects: 24
Study 10208393 — intervention group
Group type: COMPARATOR
Intervention: Non-filtered blood products (group A)
Number of subjects: 24
Study 7829619 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 28
Study 7829619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 28
Study 7829619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2196064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (NaCit)
Number of subjects: 8
Study 2196064 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 8
Study 350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 200
Study 350250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31993781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) 1500 mg/1.73 m2
Number of subjects: 13
Study 31993781 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Placebo)
Number of subjects: 13